PURDUE
OFFICE OF TECHNOLOGY COMMERCIALIZATION

Innovation Infosheet
Downloaded August 8, 2022

Improved Retroviruses for Gene Therapy

Track Code: 61136

Categories:
- Biotechnology

Keywords:
- Antivirals
- Biotechnology
- Drug Development
- Gene & Cell Therapy

Transducing cells with viral vectors to deliver novel nucleic acids requires a specific ligand or envelope glycoprotein on the virus surface to bind to a receptor on a target cell. By changing the ligand on the virus (pseudotyping), it is possible to enhance the transduction efficiency towards target cell types. For this technology, Ebola glycoprotein-pseudotyped retroviruses were produced for gene transduction into the lung and other tissues and for the study of Ebola virus entry into cells.

Researchers at Purdue University have developed a technology that allows quantitative measurement of virus entry into host cells and determination of the effectiveness of reagents that inhibit entry. This technology also allows for the production of Ebola glycoprotein-pseudotyped retroviruses with markedly improved titers, making the practical use of such viruses more feasible.

Advantages:
- Allows gene therapy of the lung using pseudotyped retroviruses
- Improved safety and efficiency

Potential Applications:
-Medical/Healthcare
-Pharmaceuticals
-Drug Development
-Antivirals
-Gene/Cell Therapy

People:
- Sanders, David A (Project leader)
- Davidson, Beverly
- Jeffers, Scott A

- McCray, Jr., Paul B
- Sanchez, Anthony
- Sinn, Patrick L

Intellectual Property:

Application Date: December 2, 2004
Type: Utility Patent
Country of Filing: United States
Patent Number: 7,981,656 B2
Issue Date: July 19, 2011

Application Date: June 4, 2003
Type: PCT-Patent
Country of Filing: WO
Patent Number: (None)
Issue Date: (None)

Application Date: March 27, 2003
Type: Provisional-Patent
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Application Date: June 4, 2002
Type: Provisional-Patent
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Contact OTC:

Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org